These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38936947)

  • 81. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
    Procopio G; Bamias A; Schmidinger M; Hawkins R; Sánchez AR; Estevez SV; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Rodriguez CS; Jonasch E
    Clin Genitourin Cancer; 2019 Jun; 17(3):e526-e533. PubMed ID: 31196680
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
    Stein J; Milhem M; Vaena D
    J Oncol Pharm Pract; 2020 Jan; 26(1):232-235. PubMed ID: 30961437
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
    Ricotta R; Di Bella S
    Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
    Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
    Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.
    Bersanelli M; Facchinetti F; Tiseo M; Maiorana M; Buti S
    Curr Drug Targets; 2016; 17(15):1755-1760. PubMed ID: 26758665
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
    Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
    BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
    Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
    Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
    Pili R; Qin R; Flynn PJ; Picus J; Millward M; Ho WM; Pitot H; Tan W; Miles KM; Erlichman C; Vaishampayan U
    Clin Genitourin Cancer; 2013 Dec; 11(4):477-83. PubMed ID: 23891158
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.
    Elhalawani H; Heiba M; Abdel-Rahman O
    Clin Genitourin Cancer; 2017 Jun; 15(3):e325-e335. PubMed ID: 28189432
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
    Jung KS; Lee SJ; Park SH; Lee JL; Lee SH; Lim JY; Kang JH; Lee S; Rha SY; Lee KH; Kim HY; Lim HY
    Cancer Res Treat; 2018 Apr; 50(2):488-494. PubMed ID: 28546525
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Exploring Predictors of Hypertension Development With Pazopanib and Examining Predictive Performance Over Time.
    Kunitake M; Goto A; Sakai Y; Higuchi K; Muto I; Ueda K; Hamada T; Hiraoka K; Murotani K
    In Vivo; 2024; 38(4):1882-1890. PubMed ID: 38936947
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 99. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.